Oculis Holding AG (OCS) Operating Income (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Operating Income came in at -$27.7 million in Q1 2026, down 24.89% year-on-year from -$36.9 million in Q1 2025, and down 7.48% quarter-over-quarter from -$25.8 million in Q4 2025.
Oculis Holding AG (OCS) Operating Income (2022 - 2026) Analysis & Trends
Oculis Holding AG's Operating Income history runs 5 years deep, the most recent figure standing at -$27.7 million for Q1 2026.
- On a quarterly basis, Operating Income fell 24.89% year-over-year to -$27.7 million in Q1 2026; TTM through Mar 2026 was -$78.7 million, a 17.77% decrease from a year earlier, with the FY2025 full-year figure at -$98.5 million, down 18.38% from the prior year.
- Operating Income fell to -$27.7 million in Q1 2026 per OCS's latest filing, from -$25.8 million in the prior quarter.
- Across five years, Operating Income topped out at -$20926.9 in Q3 2024 and bottomed at -$48.5 million in Q1 2023.
- The 5-year median for Operating Income is -$16.1 million (2024), against an average of -$17.5 million.
- Biggest YoY gain for Operating Income was 99.86% in 2024; the steepest drop was 108.06% in 2024.
- Year by year, Operating Income stood at -$11.5 million in 2022, then decreased by 19.07% to -$13.7 million in 2023, then slumped by 43.44% to -$19.7 million in 2024, then plunged by 31.02% to -$25.8 million in 2025, then dropped by 7.48% to -$27.7 million in 2026.
- Per Business Quant, the three latest OCS Operating Income figures stand at -$27.7 million (Q1 2026), -$25.8 million (Q4 2025), and -$25372.2 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.75 Mn |
| Dec 31, 2025 | -25.82 Mn |
| Sep 30, 2025 | -25,372.22 |
| Jun 30, 2025 | -25.09 Mn |
| Mar 31, 2025 | -22.22 Mn |
| Dec 31, 2024 | -19.70 Mn |
| Sep 30, 2024 | -20,926.93 |
| Jun 30, 2024 | -24.86 Mn |
| Mar 31, 2024 | -17.56 Mn |
| Dec 31, 2023 | -13.74 Mn |
| Sep 30, 2023 | -14.67 Mn |
| Jun 30, 2023 | -11.95 Mn |
| Mar 31, 2023 | -48.46 Mn |
| Dec 31, 2022 | -11.54 Mn |
| Sep 30, 2022 | -7.12 Mn |
| Jun 30, 2022 | -9.59 Mn |